Many efforts have been made to achieve targeted delivery of anticancer drugs to enhance
their efficacy and to reduce their adverse effects. These efforts include the development of …

In 1979, development of the first polymer drug SMANCS [styrene-co-maleic acid (SMA)
copolymer conjugated to neocarzinostatin (NCS)] by Maeda and colleagues was a …

This review critiques the benefits and drawbacks of the United Kingdom's National Early
Warning Score (NEWS). Potential developments for the future are considered, as well as the …

We performed FMEA on the existing RRS with the help of routine users of the RRS who
acted as subject matter experts and evaluated the failures for their criticality using the Risk …

Ischemic stroke is one of the major causes of death and disability. Since the currently used
treatment option of reperfusion therapy has several limitations, ongoing research is focusing …

Myocardial infarction, stroke, and pulmonary embolism are all deadly conditions associated
with excessive thrombus formation. Standard treatment for these conditions involves …

While fibrinolytic enzymes and thrombolytic agents offer assistance in treating
cardiovascular diseases, the existing options are associated with a range of adverse effects …

Thrombotic blockages within blood vessels give rise to critical cardiovascular disorders,
including ischemic stroke, venous thromboembolism, and myocardial infarction. The current …

Cardiovascular diseases (CVDs), mainly caused by thrombosis complications, are the
leading cause of mortality worldwide, making the development of alternative treatments …

Background Secondary polycythemia is an acquired condition characterized by an elevation
in red blood cell (RBC) mass either in response to tissue hypoxia or inappropriate …